Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT00868647
Other study ID # RFAII
Secondary ID
Status Suspended
Phase Phase 2
First received March 23, 2009
Last updated August 28, 2009
Start date June 2007

Study information

Verified date August 2009
Source Seattle Children's Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a single-center, Phase II study including only patients on whom a decision to conduct radiofrequency ablation (RFA) has already been made. The primary objective of this study assess if quality of life was improved by RFA as assessed at baseline, 3 and potentially 6 and 12 months following RFA for the benign lesions.

RFA is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using an electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.

RF ablation is an alternative for local tumor control when other treatments (surgery, radiotherapy or chemotherapy) are not feasible (less effective or at higher risk). Thermal ablation at times is the only remaining alternative for patient cure, prolonged survival or palliation. Cryotherapy, and microwave, laser and focused ultrasound are alternative thermal ablation techniques used in adults but there has been no experience in children with these alternative methods.

To be eligible for this study, patients must have acquired lesions at < 21 years of age (central nervous system lesions are excluded from this study). Study participants will have the RFA procedure performed at Seattle Children's and will have follow-up evaluations at various time points post-RFA.


Recruitment information / eligibility

Status Suspended
Enrollment 60
Est. completion date
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Lesion acquired in childhood (at <21 years of age)

- Any lesion location except CNS

- Any malignant tumor or metastasis

- Any benign lesion (e.g. desmoids, venous or lymphatic vascular anomalies, aneurysmal bone cysts, osteoid osteoma, tongue hypertrophy, or painful neuropathy)

- Patients with malignant disease have had histologic confirmation of disease at initial diagnosis.

- = 90 day life expectancy

- Potential benefit of RFA outweighs risk as determined by PI

- Other local tumor control measures are not recommended for malignant lesion based on review in multidisciplinary team conference or the patient refuses recommended local tumor control measures

- The patient is not expected to become short of breath at rest after RFA (forced vital capacity =33% of normal by pulmonary function tests) if pulmonary RFA is considered

Exclusion Criteria:

- Patients with uncontrolled infection.

- Patients with co-morbidities affecting inclusion criteria above.

- Patients who are pregnant and/or breastfeeding.

- Patients who had a change in chemotherapy within one month before RFA

- Patients who have planned change in chemotherapy and/or radiation therapy (to same site as RFA) interventions within the first three months following RFA.

- Patients should not be considered for pulmonary RFA if they have poorly compliant lungs (recently required mechanical ventilation) or require supplemental oxygen.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Radiofrequency ablation (RFA)
Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.

Locations

Country Name City State
United States Seattle Children's Hospital Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Seattle Children's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess if quality of life was improved by RFA for the benign lesions baseline, 3 months and potentially 6 and 12 months following RFA No
Secondary Assess the response to RF ablative therapy by pain relief from painful benign or malignant lesions. baseline, 3 months and potentially 6 and 12 months following RFA No
Secondary Evaluate the rate of short-term ablation of benign lesions produced by RFA baseline, 3 months and potentially 6 and 12 months following RFA No
Secondary Assess toxicity related to all RFA procedures using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 within 3 months (potentially 6-12 months) following RFA Yes
Secondary Assess the response to RFA by malignant tumor markers (e.g. AFP) 1, 3, 6, and 12 months following RFA No
Secondary Assess if quality of life was improved by RFA for patients with malignant lesions baseline, 3, 6 and 12 months No
Secondary Evaluate the proportion of malignant lesions that show short-term ablation produced by RFA. 3 months post Radiofrequency Ablation (RFA), as compared to 1 month post RFA imaging No
Secondary Determine the rate of durable ablation in malignant lesions that achieve short-term ablation by RFA 12 months post RFA No
Secondary Assess the time to malignant tumor progression (as defined by RECIST) of lesions treated with RFA 1, 3, 6, and 12 months post RFA No
See also
  Status Clinical Trial Phase
Completed NCT01193595 - Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors Phase 1
Terminated NCT01001221 - Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor Phase 1/Phase 2
Completed NCT01095302 - Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors Phase 1
Completed NCT01021150 - Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors Phase 1
Completed NCT01087021 - Effect of Cabazitaxel on the QTc Interval in Cancer Patients Phase 1
Completed NCT01063946 - A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor Phase 1
Terminated NCT02706197 - Oxygen Measurements in Subcutaneous Tumors by EPR Oximetry Using OxyChip N/A
Terminated NCT03321903 - EPR Tumor Oximetry With CE India Ink